• Users Online: 287
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 27  |  Issue : 1  |  Page : 15-20

Evaluation of serum endoglin as noninvasive marker in hepatocellular carcinoma

1 Department of Internal Medicine, Al Azhar University, Cairo, Egypt
2 Department of Tropical Medicine, Al Azhar University, Cairo, Egypt
3 Department of Clinical and Chemical Pathology, National Research Center, Cairo, Egypt

Correspondence Address:
Rehab A Mohamed
Kolyet Tegara St, Banha, Qalubbia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-7782.155832

Rights and Permissions

Introduction Hepatitis C viral (HCV) infection is a major risk factor for liver cirrhosis, liver failure, and hepatocellular carcinoma (HCC). A number of laboratory-based methods has been developed for the noninvasive diagnostic evaluation of HCC. Endoglin (CD105) is a homodimeric membrane glycoprotein expressed on endothelial cells that can bind to transforming growth factor-b1 and transforming growth factor-b3. Aim of the study The aim of this study was to evaluate the diagnostic value of endoglin and alpha-fetoprotein (AFP) in patients with chronic HCV infection with and without HCC. Patients and methods A total of 50 HCV patients were chosen and divided into two groups, group I (26 cirrhotic patients) and group II (24 HCC patients), and compared with group III (10 healthy volunteers) as controls. For all participants, thorough clinical examination, blood picture, liver function tests, HCV antibody, AFP, and serum endoglin were performed. Abdominal ultrasound, abdominal triphasic computed tomographic (CT) scan, and liver biopsy for those diagnosed HCC by triphasic CT were performed. Results We found highly significant increase in serum endoglin in HCV patients with HCC (group II) compared with HCV patients with liver cirrhosis (group I) and controls (group III). There was significant positive correlation between serum endoglin and aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, and AFP. In addition, there was significant negative correlation between serum endoglin and hemoglobin, albumin, and prothrombin concentration. The cutoff value for serum AFP for which HCC is suspected was greater than 250 ng/ml with sensitivity 79% and specificity 89%, whereas the cutoff value for serum endoglin was greater than 10.57 ng/ml with sensitivity 70% and specificity 81%. Conclusion Serum Endoglin is a promising tumor marker that may be used with serum AFP as noninvasive technique to aid diagnosis of HCC.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded335    
    Comments [Add]    
    Cited by others 3    

Recommend this journal